D Pectasides1, E Pectasides2, G Papaxoinis1, C Andreadis3, G Papatsibas1, G Fountzilas4, K Pliarchopoulou1, A Macheras5, G Aravantinos6, T Economopoulos1. 1. 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece. 2. 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece. Electronic address: pectasid@otenet.gr. 3. Department of Medical Oncology, Theagenion Cancer Hospital, Thessaloniki, Greece. 4. Department of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. 5. 3rd Department of Surgery, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece. 6. 3rd Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
Abstract
OBJECTIVE: The objective of this retrospective study was to determine the clinical outcomes of patients with primary fallopian tube carcinoma (PFTC) treated with paclitaxel and platinum analogue-based combination chemotherapy following primary cytoreductive surgery. METHODS: Sixty-four patients with the diagnosis of PFTC were identified through the gynecology service database and the tumor registry of 4 different institutions. The majority of patients (48/64, 75%) were treated with carboplatin AUC (area under curve) 6 and paclitaxel 175 mg/m(2) as a 3 h infusion. RESULTS: Among 28 patients with measurable disease, we observed 19 (68%) complete clinical and 7 (25%) partial responses for an overall response rate of 93%. After a median follow-up of 40 months (3+-134+ months), the 5-year survival rate of the entire population was 70% (median overall survival [mOS] not reached) and the median time to tumor progression (mTTP) was 81 months (95% CI: 53-109). Stage and residual disease were of prognostic significance. The mTTP was not reached in patients with stage I/II and was 38 months for patients with stage III/IV (p=0.004). The mOS for patients with stage I/II was not reached, whereas it was 62 months for those with stage III/IV (p=0.057). The mTTP was 86 and 23 months for patients with residual disease <2 cm and >2 cm, respectively (p<0.001). The mOS was not reached for patients with residual disease <2 cm, while it was 36 months for residual disease >2 cm (p<0.001). CONCLUSION: Optimally cytoreduced patients with PFTC treated with platinum and paclitaxel-based chemotherapy regimen have an excellent possibility of survival.
OBJECTIVE: The objective of this retrospective study was to determine the clinical outcomes of patients with primary fallopian tube carcinoma (PFTC) treated with paclitaxel and platinum analogue-based combination chemotherapy following primary cytoreductive surgery. METHODS: Sixty-four patients with the diagnosis of PFTC were identified through the gynecology service database and the tumor registry of 4 different institutions. The majority of patients (48/64, 75%) were treated with carboplatin AUC (area under curve) 6 and paclitaxel 175 mg/m(2) as a 3 h infusion. RESULTS: Among 28 patients with measurable disease, we observed 19 (68%) complete clinical and 7 (25%) partial responses for an overall response rate of 93%. After a median follow-up of 40 months (3+-134+ months), the 5-year survival rate of the entire population was 70% (median overall survival [mOS] not reached) and the median time to tumor progression (mTTP) was 81 months (95% CI: 53-109). Stage and residual disease were of prognostic significance. The mTTP was not reached in patients with stage I/II and was 38 months for patients with stage III/IV (p=0.004). The mOS for patients with stage I/II was not reached, whereas it was 62 months for those with stage III/IV (p=0.057). The mTTP was 86 and 23 months for patients with residual disease <2 cm and >2 cm, respectively (p<0.001). The mOS was not reached for patients with residual disease <2 cm, while it was 36 months for residual disease >2 cm (p<0.001). CONCLUSION: Optimally cytoreduced patients with PFTC treated with platinum and paclitaxel-based chemotherapy regimen have an excellent possibility of survival.
Authors: Charlotte Vaysse; Cyril Touboul; Thomas Filleron; Eliane Mery; Eva Jouve; Pierre Leguevaque; Philippe Morice; Eric Leblanc; Denis Querleu Journal: J Gynecol Oncol Date: 2011-03-31 Impact factor: 4.401
Authors: Kemal Gungorduk; Ibrahim E Ertas; Aykut Ozdemir; Emrah Akkaya; Elcin Telli; Salih Taskin; Mehmet Gokcu; Ahmet Baris Guzel; Tufan Oge; Levent Akman; Tayfun Toptas; Ulas Solmaz; Askın Dogan; Mustafa Cosan Terek; Muzaffer Sanci; Aydin Ozsaran; Tayyup Simsek; Mehmet Ali Vardar; Omer Tarik Yalcin; Sinan Ozalp; Yusuf Yildirim; Firat Ortac Journal: Cancer Res Treat Date: 2014-11-17 Impact factor: 4.679
Authors: Shakuntala P Nanaiah; Praveen S Rathod; Namrata N Rajkumar; Rajshekar Kundargi; Anbukkani Subbian; Pallavi V Ramachandra; Shobha Krishnappa; Abhilasha Narayan; Uma K Devi; Bafna D Uttamchand Journal: ScientificWorldJournal Date: 2014-02-13